Aim: The objective of this literature review was to identify current aspects of the diagnosis, treatment, and management of patients with human papillomavirus. Materials and Methods: Pubmed, Google Scholar, Web of Science, and Scopus databases were used to search for materials on current aspects of the diagnosis, treatment and management of patients with human papillomavirus. Results : Active screening should be carried out at the age of 25-35: PAP test - annually, Co-testing (liquid cytology + papillomavirus PCR) after a year. The severity of the diagnosis is determined by the degree of replacement of normal stratified epithelium with mitotically active basal-like epithelium. (<1/3=CIN 1, <2/3=CIN 2, ˃2/3=CIN 3). In 2012, the LAST nomenclature based on p16 staining was adopted for CIN grading: p-positive combines with p CIN 3, forming HSIL, CIN 2, negative for p16, combines with CIN1, forming LSIL. Conclusions: The goal of the screening program is to detect and treat high-grade precancer and prevent the development of cancer. Detection of LSIL (CIN1) is carried out by HPV testing and cervical screening, and the diagnosis is verified by histology. Most guidelines talk about surveillance from 18 years of age for 2 years for CIN 1. Diagnosis of persistent infection with HPV 16, 18, 31, 33 and others, and not the presence of CIN1, determines the risk of developing CIN 3.